Compare Nerdwallet Inc (NRDS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs TG Therapeutics Inc — how do they compare? Nerdwallet Inc trades at $9.68 (market cap $625.17M), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 13.1× Nerdwallet Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and TG Therapeutics Inc for 16 Days on average.
| NRDS | TGTX | |
|---|---|---|
Market Cap | $625.17M | $8.16B |
Volume | 1,321,316 | 1,735,121 |
Sector | Media | Health |
52-Week High | $15.93 | $59.06 |
52-Week Low | $7.58 | $26.94 |
Typical Hold Time | 45 Days | 16 Days |
Enterprise Value | $539.47M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.82, up 8.04% with strong technical momentum. The company shows improving fundamentals with 2025 revenue reaching $836.6M and net income of $48.7M, representing a 5.82% margin. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81. Analyst sentiment remains positive with 66.7% buy ratings and technical indicators signaling bullish momentum.
The outlook remains constructive as NerdWallet demonstrates revenue growth acceleration and margin expansion. Key risks include organic search pressure in credit card products and macroeconomic sensitivity. With strong cash flow generation and institutional support, the stock offers growth potential at reasonable valuations, though investors should monitor competitive pressures and execution on guidance.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
